Objective: To assess the long-term efficacy of vasopressin (AVP) V and V receptor blockade with conivaptan, alone and in 1a 2
Introduction
blockade has aquaretic effects which are beneficial in symptomatic CHF [6, 7] . In congestive heart failure (CHF) short term activation
In heart failure in rat, rabbit, pig and dog, acute studies of neurohormonal systems preserves circulatory homeostaindicate that selective V or V receptor blockade has 1a 2 sis and maintains arterial pressure but when present in short-term metabolic, hormonal responses or hemodynamic chronic excess, these 'compensatory' systems play a role benefits [3, 8, 9] . Relatively few studies have assessed the in the development and progression of CHF [1] . Early combination of V and V receptor blockade in CHF, and 1a 2 compensatory mechanisms include activation of the symall have been acute in nature [9] [10] [11] . Two studies have pathetic nervous system, natriuretic peptides, the reninassessed the combination of V receptor blockade and 1a angiotensin system and levels of arginine vasopressin angiotensin converting enzyme (ACE) inhibition [3, 4] , but (AVP) also rise [2] . Vasopressin has adverse effects in heart to date it is not known whether V receptor blockade, or V myocardial dysfunction, alleviate symptoms and reduce dose attenuates cardiac remodeling and improves survival morbidity and mortality [12] .
in this model of CHF [16] [17] [18] . Conivaptan (YM087) is the first orally effective nonpepLeft ventricular free-wall myocardial infarction was tide antagonist of both V and V receptors [13, 14] Body weight and systolic blood pressure (SBP) were be used as an adjunct to blockade of the renin-angiotensin measured weekly between 90 and 120 min after dosing by system rather than as monotherapy in the management of one observer blinded to the treatment of each rat. SBP was heart failure, this study was designed to assess the longmeasured by the indirect tail-cuff technique (38L flatbed term efficacy of V and V receptor blockade with recorder, model 229 Amplifier, IITC Life Science, Wood1a 2
conivaptan, alone and in combination with ACE inhibition. land Hills, CA, USA) in conscious, lightly restrained rats. In particular the effect of treatment on blood pressure, During the fourth week of treatment, a randomly selected metabolic and neurohormonal parameters, and carsubset of rats (n56-9 per group) were placed in metabolic diovascular structure in the coronary artery ligation model cages and food and fluid intake, as well urine volume, of heart failure were assessed [5, 16] .
sodium and osmolality were assessed. After 4 weeks treatment, rats were killed by decapitation and trunk blood collected into prechilled lithium heparin tubes for measurement of plasma osmolality, sodium and plasma AVP, and 2. Methods tubes containing EDTA / aprotinin (kallikrein inhibitor 500 U / ml) for the measurement of atrial natriuretic peptide Experimental procedures were approved by the Austin (ANP) and plasma renin activity (PRA). The left ventricle Hospital Animal Research Ethics Committee and perand interventricular septum (LV) were dissected from the formed according to the National Health and Medical heart; weighed and fixed in 10% buffered formalin. The Research Council of Australia Guidelines for animal right ventricle (RV) and lungs were weighed. To determine experimentation.
infarct size the LV was sectioned at four levels from the Conivaptan [YM087, 49-(2-methyl-1,4,5,6-base to the apex, paraffin fixed and sections cut and stained tetrahydroimidazo[4,5-d](1)benzoazepine-6-carbonyl)-2-with Masson's trichrome. The mean epicardial and endophenylbenzanilide] monohydrochloride) was a gift from cardial scar circumference was compared to total left Yamanouchi (Tokyo, Japan). Captopril was purchased ventricular circumference to calculate total infarct size from Sigma (MO, USA). Female Sprague-Dawley rats [16] . Rats with a subendocardial infarct or infarct size of (150-200 g) from the Austin Biological Research Labs., less than 20% were excluded from analysis. (Austin, USA) and Repatriation Medical Centre were housed at 23-25 8C in a 12 h light-dark cycle with access 2.2. Analytical methods to a standard rat chow (0.4-0.6% NaCl) and normal water ad libitum.
Plasma AVP, ANP and PRA were measured by radioimmunoassay as previously described [20] [21] [22] . Urine and 2.1. Experimental design plasma osmolality were measured using a Wescor vapor pressure osmometer 5100C (Logan, UT, USA). Urine The aim of the present study was to compare in sodium was measured using an ion-selective electrode experimental CHF, the effect of 4 weeks treatment with V (ILyte, Instrumentation Lab., Italy). and V receptor blockade, and combined AVP receptor 2 blockade and ACE inhibition. The dose selected for 2.3. Statistics conivaptan was based our previous work [14] in which oral conivaptan (0.1-3 mg / kg) dose dependently inhibited
The results are presented as means6S.E.M. Longitudivasopressin binding to liver V and kidney V and V nal SBP and body weight were compared between treat1a 1a 2
receptors over 24 h. The 1 mg / kg dose of conivaptan was ment groups by ANOVA for repeated measures followed chosen as this dose caused blockade of both V and V by posthoc analysis using ANOVA and Fisher's PLSD test 1a 2
receptors measured using autoradiography and binding when appropriate. The metabolic, plasma, hormonal and techniques [14] . The dose of captopril was chosen as this tissue weight data were analyzed by ANOVA and Fisher's PLSD test. Significant differences were obtained when P,0.05.
Results
Cages were examined twice daily to assess the health of the animals. Of 160 rats operated on to tie off the coronary artery, 72% (n5115) were alive at 24 h and were randomized to vehicle (n529), conivaptan (n529), captopril (n531), or conivaptan plus captopril (Combination, n526). All sham operated rats survived (n514). captopril, n51; Combination, n51) died during the course captopril (P50.055) and significantly lowered by Combiof the study and were also excluded from the analysis.
nation treatment (P,0.01) compared to vehicle (Fig. 1) . Results are thus reported on 56 infarct rats (vehicle, n511; conivaptan, n517; captopril, n516; Combination, n512) and 14 vehicle treated, non-infarcted rats (Control). The 3.2. Metabolic parameters average infarct size was 39-43% with no significant difference among treatment groups (Table 1) .
There were no differences in urine osmolality, output or sodium excretion between Control and CHF rats (Table 1 , 3.1. Weight and systolic blood pressure Fig. 2 ). In CHF, after 4 weeks treatment, urine osmolality was reduced by conivaptan and Combination treatment Baseline body weight was similar in all groups (18262 (P,0.01) ( Table 1) . Conivaptan alone or in combination g), and all rats gained weight during the study period with captopril significantly increased urine volume. There (P,0.01). At week 4, rats treated with captopril and was a nonsignificant trend to increased urinary sodium Combination therapy had reduced body weight compared excretion with conivaptan (P50.054) and Combination to vehicle (Captopril, P,0.05, Combination, P,0.01, (P50.066) (Fig. 2) . Captopril had no significant effect on Table 1 ), with a greater reduction with Combination any renal parameter. In CHF, plasma osmolality, AVP and treatment compared to captopril (P,0.05). There was no PRA were similar to values in Control rats (Table 1) . significant difference in food intake (data not shown)
Conivaptan had no effect on plasma osmolality but inbetween the groups. creased plasma AVP (P,0.05), whilst PRA was increased Baseline systolic blood pressure was similar in all by captopril and Combination treatment (P,0.01). Plasma groups, but 4 weeks after infarction blood pressure was ANP was significantly increased in CHF compared to lower in vehicle treated CHF compared to Control rats Control rats (P,0.05), and was reduced by Combination (P,0.01). At week 4, blood pressure was even lower on treatment alone (P,0.05). 
Cardiovascular structure
Relative atria mass was not significantly changed by any treatment, but was lower in the captopril and Combination CHF rats were characterized by increased relative LV, groups. RV, atria and lung mass compared to Control rats (all P,0.01) ( Table 2 ). As expected in CHF, captopril reduced LV (P,0.01) and RV mass (P,0.05) compared to vehicle 4. Discussion (Fig. 3) . Conivaptan did not influence LV mass but significantly reduced RV mass (P,0.01), and in combina-
The long term response to vasopressin V and V 1a 2 tion with captopril reduced both LV and RV mass (P, receptor blockade in experimental CHF has not previously 0.01), as well as reducing lung mass (P,0.05) ( Table 2) . been investigated, and this is also the first study to compare and combine V and V receptor blockade and conivaptan and captopril suggesting improved vasopressin 1a 2 ACE inhibition in experimental heart failure. The major metabolism [24] as a consequence of improved renal findings of this study in heart failure were that conivaptan, function. a V and V receptor antagonist increases water excretion, Vasopressin suppresses renin release [25] , and improved 1a 2
and in combination with an ACE inhibitor, lowers blood renal flow may also explain the lack of rise in PRA with pressure, body weight, pulmonary congestion and ANP vasopressin receptor antagonism. Atrial natriuretic peptide secretion.
which is elevated in proportion to the degree of left ventricular dysfunction [26] and correlates with prognosis, 4.1. Postinfarction heart failure model was reduced only by combination treatment with conivaptan and captopril, which suggests cardiac function may The model of myocardial infarction induced heart failure have improved more with the combination than with ACE used in this study results in hemodynamic alterations and inhibition alone. Although cardiac function was not speneurohormonal changes [5, 17] similar to those seen in cifically assessed in this study, the cardiac benefits of patients with anterior myocardial infarction and results conivaptan in the dog pacing model of heart failure to using this model have clinical implications [12] . All increase cardiac output and decrease left ventricular endinfarcted rats in this study had histological verification of diastolic pressure would also be expected to reduce ANP infarct sizes, and all showed signs of pulmonary congessecretion [10]. tion. We have previously shown that heart failure in this model is characterized by cardiac remodeling with LV 4.3. Blood pressure and cardiovascular structural effects cavity dilation, hypertrophy of surviving myocardium and of conivaptan impaired systolic function [23] . With regard to neurohormonal activation, this is a compensated model of heart Combination treatment with conivaptan and captopril failure with normal renin activity and plasma vasopressin led to a small but significant fall in blood pressure in CHF, levels, but elevated natriuretic peptide levels [5, 19] .
and as the fall with captopril alone did not reach significance, this additional effect may represent V receptor and reduced urine osmolality, indicating significant inhibikidney [14] , and renal V receptors. In addition, au-2 tion of renal V receptor function. There was trend to toradiographic data from ongoing studies in rat heart 2 increased urinary sodium excretion by conivaptan but this failure indicate that both V and V receptors are blocked 1a 2
did not reach significance. In long-term (6 month) CHF following long-term (6 month) treatment with conivaptan studies, the effect of conivaptan on sodium excretion was (unpublished data). Further evidence of the V receptor 1a equivalent to vehicle (Vehicle, 0.5860.03 mmol / min / 100 blocking efficacy of conivaptan is shown by its ability to g, Conivaptan, 0.4760.05 mmol / min / 100 g, n510 / group, inhibit the pressor response to exogenous vasopressin [13], unpublished data). These results confirm acute studies in and to decrease mean arterial pressure total and peripheral dogs [10,13] and rats [14] using conivaptan, and extend resistance in heart failure [10]. them to demonstrate the aquaretic effects of conivaptan are Few studies have investigated combined V / V receptor 1a 2 maintained long term in heart failure. The renal effects of and renin-angiotensin system blockade in heart failure. conivaptan were not accompanied by an increase in plasma Experimental and clinical trials show ACE inhibitors slow osmolality, which may reflect the fact that rats had free the deterioration of the failing heart and improve long term access to water.
survival partly through reversal of the neurohumoral Treatment with nonpeptide V receptor blockers such as activation, and also through attenuation of remodeling 2 OPC-31260 [5,9] causes an aquaresis and increases plasma [18] . In real terms, the modest effect of ACE inhibitors on vasopressin [5] , and this was also seen with conivaptan. As mortality and the continued remodeling even in the face of urine volume was similar with conivaptan and combination ACE inhibition [1] highlights the need for additional therapy, the increase in plasma AVP was not able to therapy. Short-term studies in rabbits with acute left overcome V receptor blockade. A concern with selective ventricular failure [3] reported the combination of a 2 V receptor blockers is that their clinical efficacy to reduce peptide V receptor antagonist and an ACE inhibitor had 2 1a
preload is offset by unopposed activation of the V additive effects to increase cardiac output and decrease 1a receptor. However, conivaptan has the advantage that any both blood pressure and peripheral resistance [3] , but it is contribution of elevated vasopressin to systemic vasoconnot clear whether these short-term improvements persist or striction would be prevented by its V receptor blocking are associated with attenuation of ventricular remodeling. 1a
properties [6] . Interestingly, plasma vasopressin was not In this study, conivaptan had beneficial effects to regress significantly elevated with combined treatment with right ventricular hypertrophy, a marker of overload hy-pertrophy which may be due to reduced preload due to vasopressin V and V receptors with conivaptan was 1a 2
increased urine output, and / or direct cardiac effects. The associated with increased water excretion. In combination heart is known to contain V receptors [27] , and AVP is with an ACE inhibitor, conivaptan reduced blood pressure, 1a now recognized to be synthesized in the heart and vasculapulmonary congestion and plasma natriuretic peptide ture where it acts as a paracrine hormone [28, 29] . Thus levels. These results suggest that vasopressin receptor vasopressin may serve as both a circulating and as a local blockade may be useful in the treatment of heart failure as tissue hormone system in an analogous manner to the an adjunct to ACE inhibition in the management of renin-angiotensin system and may have deleterious effects vasoconstriction and fluid retention that characterizes heart on the heart when present in chronic excess. Vasopressin failure. causes hypertrophy in both isolated perfused hearts and in cardiomyocytes via the V receptor, and this effect can be 1a blocked by selective V receptor antagonism using OPC1a Acknowledgements 21268 [30] or combined V / V receptor antagonism using 1a 2
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